Baxter reports positive trial data for Vivia haemodialysis system

Baxter has announced data from new clinical studies that underlines the benefits offered by its Vivia haemodialysis (HD) system.

Results from the two trials, conducted in a clinical setting, showed acceptable clearance of uremic toxins and an overall safety profile similar to that associated with conventional HD devices.

Conducted in the US and Canada, the two studies demonstrated the device's urea clearance and dialysis adequacy, as well as the feasibility of multiple uses of the same dialyser on the same patient.

Vivia has also been shown to offer sustainability and cost-effectiveness benefits, which helped it to earn European CE Mark approval at the end of last year.

Dr Bruce Culleton, vice president and renal therapeutic area lead at Baxter, said: "We conducted the studies to evaluate the efficacy and safety of the Vivia HD system, which demonstrated its ability to provide acceptable clearance of uremic toxins, safely and reliably."

This comes after the firm last month provided an update on the impact of Advate, its groundbreaking recombinant treatment for patients with haemophilia A, which remains the most prescribed full-length recombinant FVIII worldwide and continues to show strong growth.